Alluvi, formerly BI 4744, represents a promising development in weight management therapy. This dual activator targeting both glucagon-like peptide-1 and GIP sites demonstrates compelling efficacy in clinical studies, https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/